HC Wainwright Has Lowered Expectations for Savara (NASDAQ:SVRA) Stock Price

Savara (NASDAQ:SVRA) had its price objective decreased by investment analysts at HC Wainwright from $10.00 to $6.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 69.01% from the stock’s current price.

Several other research analysts have also weighed in on the stock. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. Evercore ISI restated an “in-line” rating and set a $5.00 price target (down previously from $7.00) on shares of Savara in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Savara Stock Down 7.3 %

Savara stock traded down $0.28 during trading hours on Wednesday, hitting $3.55. The company had a trading volume of 497,604 shares, compared to its average volume of 1,199,064. The firm has a market capitalization of $584.33 million, a P/E ratio of -8.45 and a beta of 1.02. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. The firm’s fifty day moving average is $3.97 and its 200-day moving average is $4.22. Savara has a fifty-two week low of $3.28 and a fifty-two week high of $5.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, research analysts forecast that Savara will post -0.44 earnings per share for the current year.

Institutional Investors Weigh In On Savara

A number of institutional investors and hedge funds have recently modified their holdings of the business. ProShare Advisors LLC raised its stake in shares of Savara by 9.0% during the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after buying an additional 2,114 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Savara by 15.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock valued at $168,000 after purchasing an additional 4,625 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Savara by 14.9% during the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock valued at $166,000 after purchasing an additional 5,335 shares during the period. Principal Financial Group Inc. grew its holdings in Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after purchasing an additional 6,973 shares during the period. Finally, CANADA LIFE ASSURANCE Co acquired a new position in Savara during the first quarter valued at approximately $35,000. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.